Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Biogen

Halozyme Therapeutics

The healthcare sector continues to be a hotbed of innovation, with biotechnology leading the charge. From groundbreaking gene therapies to next-generation cancer treatments, biotech companies are pushing the boundaries of medicine and transforming patient care.

3 Highly Rated Biotech Stocks for Your July Buy List

CrowdStrike

D.R. Horton

Goldman Sachs

Pure Storage

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Harmony Biosciences Holdings

MiMedx Group

MEI Pharma

Procaps Group SA

SCYNEXIS

United Therapeutics

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $750 million. Sales of Opzelura, one of the company's gems, totaled $85.7 million in the first quarter of 2024, up 51.4% year-on-year.

Incyte: The Worst Has Been Avoided

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Final Results of Tender Offer.

Incyte Announces Final Results of Tender Offer

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Preliminary Results of Tender Offer.

Incyte Announces Preliminary Results of Tender Offer

Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Malignant Mesothelioma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.

Malignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific Interventions

WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Escient Pharmaceuticals.

Incyte Completes Acquisition of Escient Pharmaceuticals

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings.

Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Thro.

Incyte to Present at Upcoming Investor Conference

Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.

Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week

The stock price of Incyte Incyte , a biopharmaceutical company, trades at $58 per share, about 43% below its peak level of $100 seen in January 2021. INCY stock was trading at around $76 in early June 2022, just before the Fed started increasing rates, and is now 24% below that level, compared to a substantial 38% gain for the S&P 500 during this period.

How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash?

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO24--Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress.

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

Major U.S. equities indexes were mixed and little changed Monday to kick off a new trading week that will provide investors with a few key economic data points.

S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback Plan

Biotech Incyte Corp. said Monday its board has approved a share buyback of up to $2 billion and the company has commenced a modified Dutch auction tender for up to $1.67 billion worth.

Incyte to buy back $1.67 billion of its own stock in Dutch auction tender

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock.

Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock

BioMarin Pharmaceutical

We live in the best of times where life is not capped at 45 or 50 years of age, all thanks to wonderful discoveries in the field of biotechnology. The resources being invested to produce new drugs and treatment methodologies are increasing day by day.

The 3 Best Biotech Stocks to Buy in May 2024

Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.

Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates

Incyte Corporation (NASDAQ:INCY ) Q1 2024 Earnings Conference Call April 30, 2024 8:00 AM ET Company Participants Ben Strain - Associate VP, IR Hervé Hoppenot - CEO Christiana Stamoulis - CFO Pablo Cagnoni - President, Head of Research & Development Matteo Trotta - EVP, General Manager, U.S. Dermatology Steven Stein - CMO Barry Flannelly - General Manager, North America Conference Call Participants Kelly Shi - Jefferies David Lebowitz - Citi Kripa Devarakonda - Truist Securities Michael Schmidt - Guggenheim Marc Frahm - TD Cowen Brian Abrahams - RBC Capital Markets Vikram Purohit - Morgan Stanley Derek Archila - Wells Fargo Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Salveen Richter - Goldman Sachs Eric Schmidt - Cantor Fitzgerald Jay Olson - Oppenheimer Matt Phipps - William Blair Evan Seigerman - BMO Capital Markets Ren Benjamin - Citizens JMP Gavin Clark-Gartner - Evercore ISI Operator Hello and welcome to Incyte First Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Incyte Corporation (INCY) Q1 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%.

Incyte misses quarterly profit on weak sales of lead drug

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs.

Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte Corporation shares have underperformed lately, but the company has shown solid growth, profitability, and increased net cash position. Diversification from its blockbuster drug Jakafi has been slow, but overall appeal has improved. The company's valuation is low, and with potential product launches and acquisitions, there is potential for future share price appreciation.

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Incyte Stock (INCY)